Publications - Reviews
T cell adoptive immunity for cancer | Gene-modified T cells for HIV | Dendritic cell vaccines for cancer | Reviews
| Publication |
PMID |
PMCID |
| Chiang CL, Kandalaft L, Tanyi JL, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Smith L, Coukos G. A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clin Cancer Res. 2013 Sep 1;19(17):4801-15. DOI: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9. |
23838316 |
PMC4049094 |
| Kandalaft, LE, Powell Jr., DJ, Chiang, CL, Tanyi, J, Kim, S, Bosch, M, Montone, K, Mick, R, Torigian, DA, Levine, BL, June, CH, Coukos, G. Autologous Lysate-pulsed Dendritic Cell Vaccination Followed by Adoptive Transfer of Vaccine-primed Ex Vivo Costimulated T-cells in Recurrent Ovarian Cancer Oncoimmunology 2(1): 1-9, January 2013 Notes: eLocation ID: e22664. Oncoimmunology. 2013 Jan 1;2(1):e22664. DOI: 10.4161/onci.22664. |
23482679 |
PMC3583933 |
| Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012 Sep 1;118(17):4354-62. DOI: 10.1002/cncr.26734. Epub 2012 Jan 17. |
22252842 |
PMC3330145 |
| Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Czerniecki BJ. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother. 2012 Jan;35(1):54-65. DOI: 10.1097/CJI.0b013e318235f512. |
22130160 |
PMC3241864 |
| Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother. 2012 May;61(5):629-41. DOI: 10.1007/s00262-011-1081-8. Epub 2011 Oct 22. |
22021066 |
|
| Czerniecki BJ, Koski GK, Kolodovsky U, Xu Sh, Cohen PA, Mick R, Niesenabum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion. Cancer Res. 2007 Feb 15;67(4):1842-52. DOI: 10.1158/0008-5472.CAN-06-4038. Epub 2007 Feb 9. |
17293384 |
|
